Ligand id: 7335

Name: nivolumab

Immunopharmacology Comments
Nivolumab is an immuno-oncology drug, targeting various cancers via blockade of the PD-1 immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. Checkpoint inhibition is a mechanism of action now widely accepted as efficacious for cancer immunotherapy [16,19].
Immunopharmacology Disease
Disease X-Refs Comment References
Lymphoma, Hodgin, Classic; CHL Disease Ontology: DOID:8567
OMIM: 236000
Approved drug for cHL.
Renal cell carcinoma Disease Ontology: DOID:4450
A combination therapy of nivolumab plus ipilimumab was granted FDA approval in April 2018 , for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma 2,14